Biomoda, Inc. (OTC Bulletin Board: BMOD - News), is a biopharmaceutical company focusing on early cancer detection technology. Biomoda's non-invasive, cell-targeting technology is globally patented for the detection of pre-cancerous and cancerous conditions in all human tissue. This technology, based on a compound called Tetrakis Carboxy Phenyl Porphine (TCPP), was developed at Los Alamos National Laboratories. Biomoda obtained a worldwide exclusive license to the TCPP technology from Los Alamos National Laboratories, and began new research broadening the scope of the original patent and technology. For more information about Biomoda, please visit the company's website at http://www.biomoda.com.